Hey! Someone besides me knows how aspirin was designed to be used!
To answer your question , I'm going to use an exerpt from a Dec.write up from Cox.
NNVC is keenly aware of this and are proceeding accordingly.It is in your (and our) best interests that they succeed.
Exerpt as follows:
Predictions regarding equities are a little more difficult — because of uncontrollable and unknowable factors. As a result, I spend a lot of time thinking about what I don’t know. Recently, I’ve been thinking about two of our companies because of what I don’t know. Specifically, what I don’t know is when Big Pharma is going to pull the trigger.
Unfortunately, often the people who make decisions for big pharmaceuticals are not even scientists. They’re lawyers and accountants. Therefore, you can’t “know” how they’re going to deal with a truly revolutionary new therapy.
I’m talking about NanoViricides (OTCBB: NNVC) and Pro-Pharmaceuticals (OTCBB: PRWP). These two companies both own brand-new and completely disruptive sciences with truly remarkable potential to save lives and make investors rich. In both their cases, their science is so outside conventional thinking that they inspire uninformed skepticism.
I don’t mind that, of course, because this is how all truly disruptive scientific breakthroughs are treated initially. Eventually, with sufficient evidence, the right people catch on. In fact, both companies have established research collaborations with eminent scientists and have progressed successfully through a series of important clinical tests. I know that the scientific community is beginning to get the message.
So now I find myself worrying that Big Pharma is going to pull the trigger too soon. That’s what happened to us with Medarex. They were acquired, so stockholders only tripled their money. In my fantasies, both Pro-Pharmaceuticals and NanoViricides will retain control of their technologies. They will continue to amass data, forming partnerships and earning licensing fees until they are worth many thousands of percent more than they are today.
The company in most danger of premature acquisition is Pro-Pharmaceuticals, because they are closest to Phase III studies for Davanat taken in conjunction with chemo. Increasingly, however, it is becoming clear that the field of glycoscience is far bigger than a drug that does away with the side effects of chemo.
Research has shown that Pro-Pharmaceuticals’ simple, safe carbohydrates increase survival rates of cancer vaccine users by a factor of three.
If you followed the run-up of Dendreon Pharmaceuticals’ stock due to the approval of their prostate cancer vaccine, you know what kind of potential this brings to the table.
Moreover, animal data have shown that the same carbohydrate reverses the fibrosis that causes liver disease. This is potentially much bigger than the cancer market. There are lots of people targeting cancer with promising new therapies on the horizon. I’ve written often, for example, about one such company — Bexion Pharmaceuticals.
I know of nobody but Pro-Pharmaceuticals, however, with a real cure for liver disease in the works. Before 2000, the U.S. spent over a $1.5 billion a year to treat liver disease annually… twice that in indirect costs. Those costs are increasing rapidly as the population ages.
It’s true that animal studies don’t always translate into human cures, but the galectins targeted in rats are the same as human galectins. On top of that, we also know that the drug is safe because it is essentially an indigestible food that does not degrade in the system, as so many promising drugs do. With Dr. Scott Friedman, the president of the American Association for the Study of Liver Diseases, now pushing the liver research forward, the industry is going to notice.
We don’t increase buy prices here for the simple reason that analysts are graded on the difference between buy and current stock prices. On the other hand, remember that Pro-Pharmaceuticals has a capitalization of only $50 million or so. That’s barely peanuts in pharma terms.
Lots of licensing deals run into the hundreds of millions. This raises the distinct possibility that at some point in the not very distant future, some behemoth is going to figure out that it would be way cheaper simply to buy the company than negotiate individual drug deals.
In a rational world, Pro-Pharmaceuticals would be worth at least four or five times its current capitalization. If it were now, I’d be a lot less worried about the future of this stock.
I promise to keep you updated as this continues to unfold.
AI
